Avanos Medical, Inc. $AVNS Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lessened its stake in Avanos Medical, Inc. (NYSE:AVNS) by 89.0% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 8,712 shares of the company’s stock after selling 70,180 shares during the quarter. SG Americas Securities LLC’s holdings in Avanos Medical were worth $122,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in AVNS. AQR Capital Management LLC raised its holdings in Avanos Medical by 46.4% in the first quarter. AQR Capital Management LLC now owns 192,864 shares of the company’s stock valued at $2,700,000 after acquiring an additional 61,095 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Avanos Medical by 4.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company’s stock worth $386,000 after acquiring an additional 1,121 shares in the last quarter. Millennium Management LLC grew its holdings in Avanos Medical by 508.3% during the 1st quarter. Millennium Management LLC now owns 547,740 shares of the company’s stock worth $7,849,000 after acquiring an additional 457,703 shares in the last quarter. Empowered Funds LLC increased its position in shares of Avanos Medical by 5.4% in the 1st quarter. Empowered Funds LLC now owns 162,182 shares of the company’s stock valued at $2,324,000 after purchasing an additional 8,348 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Avanos Medical by 17.1% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company’s stock valued at $2,018,000 after purchasing an additional 20,541 shares during the last quarter. 95.17% of the stock is owned by institutional investors and hedge funds.

Avanos Medical Stock Performance

NYSE AVNS opened at $24.95 on Tuesday. The company has a fifty day moving average of $24.87 and a two-hundred day moving average of $18.44. The company has a market capitalization of $1.17 billion, a PE ratio of -15.49 and a beta of 1.57. Avanos Medical, Inc. has a 1 year low of $9.30 and a 1 year high of $25.49. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.48 and a quick ratio of 1.40.

Avanos Medical (NYSE:AVNS) last posted its earnings results on Tuesday, May 5th. The company reported $0.22 EPS for the quarter, topping analysts’ consensus estimates of $0.16 by $0.06. Avanos Medical had a positive return on equity of 5.39% and a negative net margin of 10.39%.The business had revenue of $182.20 million for the quarter, compared to analysts’ expectations of $170.00 million. During the same quarter in the previous year, the firm earned $0.26 earnings per share. The business’s revenue was up 8.8% compared to the same quarter last year. As a group, analysts expect that Avanos Medical, Inc. will post 1.06 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Zacks Research raised shares of Avanos Medical from a “strong sell” rating to a “hold” rating in a research report on Friday, June 5th. Weiss Ratings raised Avanos Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 22nd. Finally, Wall Street Zen cut Avanos Medical from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. One equities research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Avanos Medical currently has an average rating of “Reduce”.

Avanos Medical Profile

Avanos Medical is a global medical technology company that develops and markets a broad portfolio of medical devices intended to improve patient outcomes in hospital, outpatient and post-acute care settings. The company’s products focus on three core therapy areas—pain management, enteral feeding and respiratory care—designed to help clinicians manage post-operative pain, deliver nutrition support and assist breathing for patients across a variety of acute and chronic conditions.

In its pain management segment, Avanos offers both non-opioid drug delivery systems and cryoanalgesia devices, including ambulatory infusion pumps and cooled radiofrequency ablation platforms.